Drugs / BGB-30813
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05904496 | Jul 2023 → Aug 2025 | cancer | BeiGene | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-30813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05904496 ↗ |
| Action | Inhibit | “DGKζ Inhibitor BGB-30813” NCT05904496 ↗ |
| Route | Oral | “BGB-30813 will be given orally” NCT05904496 ↗ |